{"prompt": "['Tofacitinib', 'A3921284 NON-INTERVENTIONAL STUDY PROTOCOL', 'Amended, 12-December-2018', '10. RATIONALE AND BACKGROUND', 'Rheumatoid arthritis (RA) is an autoimmune, chronic, systemic disorder, which affects', 'around 1% of world population. It is characterized by synovial membranes swelling, causes', 'joints swelling, stiffness and pain, which lead to cartilage and bone tissue progressive', 'erosion and destruction at the affected joints. Between 17.85%-40.9% of patients with RA', 'may experience extra-articular manifestations which may involve skin, eye, respiratory,', 'oral, cardiovascular, neurological, hematological, and/or vascular function (1-4). Patients', 'with RA are also likely to experience depression, sexual dysfunction, and social', 'relationships disruption.', 'In addition, RA represents an important burden for informal caregivers (spouse, relatives)', 'who spend a lot of time helping patients with their daily activities, personal care, social', 'activities and financial matters (12,13). This caregiver overload contributes substantially to', 'loss of productivity and to the total disease burden.', 'There is no cure for RA, the treatment goals are to relieve disease signs and symptoms,', \"control disease activity, improve physical function and patient's quality of life and inhibit\", 'structural-damage progression in the disease course. Treatment for RA is typically initiated', 'with nonsteroidal anti-inflammatory drugs (NSAIDs) and/or low-dose glucocorticoids and', 'conventional synthetic disease modifying anti-rheumatic drugs (DMARDs) (typically', 'Methotrexate (MTX)) as soon as possible after diagnosis (14-16).', 'Biological therapies are drugs that emerged almost a decade ago for preventing or reducing', 'the swelling caused by Rheumatoid Arthritis (RA) after failure from a conventional drug', 'such as methotrexate. These are molecules consisting of proteins produced by living', 'organisms that act on very specific mechanisms of a cell, organ or system (1-4) .', 'Furthermore, there are also chemically synthesized molecules produced from chemical', 'precursors for the treatment of arthritis; tofacitinib is a chemically synthesized drug', \"targeted to block the pathway of an enzyme called Janus kinase (JAK), involved in body's\", 'immune response, and fighting swelling from inside the cell.', 'Recently, American College of Rheumatology (ACR) recommended in established RA, if', 'disease activity remains moderate or severe despite conventional DMARD monotherapy,', 'the rheumatologist can use a combination of traditional DMARDs or add a Tumor Necrosis', 'Factor (TNF) inhibitor or a non-TNF biological DMARD or tofacitinib (17). Also, ACR', 'recommended tofacitinib in patients who remain moderate and severe despite use of at least', 'a TNF inhibitor or non-TNF biologic agents (17). Within the group of biological DMARDs', 'there are nine compounds identified (18), five TNF inhibitor agents: adalimumab,', 'Page 18 of 64']['Tofacitinib', 'A3921284 NON-INTERVENTIONAL STUDY PROTOCOL', 'Amended, 12-December-2018', 'certolizumab pegol, etanercept, golimumab and infliximab; abatacept, a selective T-cell co-', 'stimulation modulator; rituximab, an anti-B cells monoclonal antibody; tocilizumab, a', 'monoclonal antibody against the interleukin-6 receptor, and anakinra an interleukin-1', 'inhibitor.', 'Tofacitinib is an orally-administered chemically synthesized molecule that inhibits the', 'enzymes Janus kinase 1 and 3, and therefore interferes with the Janus Kinase - Signal', 'Transducer and Activator of Transcription (JAKSTAT) signaling pathway, thereby', 'preventing replication of genetic information that leads to disease progression. It is used for', 'treating moderate to severe RA when there is an inadequate response or intolerance to', 'DMARDs.', 'Tofacitinib 5 mg twice daily (BID) and tofacitinib 10 mg BID have demonstrated', 'consistent efficacy in reducing the signs and symptoms of RA, and showed improvements', 'in the Patient-Reported Outcomes (PROs), with manageable safety profiles across six Phase', '3 studies, either as monotherapy or in combination with conventional disease-modifying', 'antirheumatic drugs (DMARDs) (5-10).', 'Tofacitinib belongs to the therapeutic group L04AA29, it may be administered in', 'monotherapy or in combination with MTX or other DMARDs. The recommended dose is 5', 'mg twice daily, it should not be used in patients with serious liver failure; in case of', 'lymphopenia, neutropenia or anemia it is recommended to suspend the treatment and the', 'same applies if the patient develops a serious infection, until the infection is controlled (19).', 'In the United States, the Food and Drug Administration (FDA) approved the use of', 'tofacitinib for the treatment of RA in 2012. In Colombia, the \"Instituto Nacional de', 'Vigilancia de Medicamentos V Alimentos\" (INVIMA) approved the presentation of', 'tofacitinib 5 mg under Health Registration No. 2013M-0014423 on July 26, 2013. In Chile,', 'the Instituto de Salud P\u00fablica (ISP) approved the same presentation under Health', 'Registration No. F-20759/14 on January 8, 2014. In Peru the \"Direcci\u00f3n General de', 'Medicamentos e Insumos V Drogas\" (DIGEMID) approved tofacitinib 5 mg under the', 'register EE-00112 on September 25, 2013. In Ecuador the \"Agencia Nacional de', 'Regulaci\u00f3n Control Vigilancia Sanitaria\" (ARCSA) approved tofacitinib 5 mg under the', 'register 172-MEE-0314 on March 25, 2014.', 'Six phase III randomized clinical trials have been conducted with tofacitinib in different', 'stages of arthritis in which the drug is compared to placebo or methotrexate. These studies', 'demonstrated good results related to efficacy and safety of tofacitinib (5-10). Currently,', 'there are no data in real life conditions comparing tofacitinib with biological DMARDs', 'Page 19 of 64']\n\n###\n\n", "completion": "END"}